AOD-9604 vs Tesamorelin

At a glance

Mechanism contrast

AOD-9604 is a modified C-terminal fragment of human growth hormone (residues 176-191 with an added N-terminal tyrosine for stability). It retains the lipolytic activity of full-length HGH while lacking the IGF-1-mediated growth and insulin-antagonising effects, because the receptor sequence that drives those effects sits in a different region of the parent hormone. Mechanism studies suggest the fragment biases adipose tissue toward fatty-acid oxidation through β3-adrenergic-receptor-mediated lipolysis and inhibition of acetyl-CoA carboxylase.

Tesamorelin is a different beast entirely — a GHRH(1-44) analogue stabilised against DPP-4 cleavage, which binds the GHRH receptor on pituitary somatotropes and stimulates the body's own pulsatile growth-hormone release. The downstream effect of that GH pulse is broad: IGF-1 induction, lipolysis, modulation of glucose handling, and — importantly for the indication tesamorelin was developed for — preferential reduction of visceral rather than subcutaneous adipose tissue.

In short: AOD-9604 isolates lipolysis without touching the GH axis. Tesamorelin activates the GH axis and gets lipolysis as one of its many downstream effects. For mechanism-isolation studies the distinction matters enormously.

Clinical evidence base

Tesamorelin has the deeper human evidence record. Falutz et al. published the pivotal Phase 3 trial in NEJM 2007 (PMID 17671254) in HIV-associated lipodystrophy, demonstrating ~15-18% reduction in visceral adipose tissue volume over 26 weeks of 2 mg daily subcutaneous administration. A follow-up trial extended the safety record; tesamorelin is FDA-approved as Egrifta for HIV-associated lipodystrophy and the data has been used as the reference for broader VAT-research designs ever since.

AOD-9604's human evidence file is thinner. Metabolic Pharmaceuticals advanced the compound through Phase 2b for adult obesity, but the trial did not reach statistically significant weight reduction versus placebo at the doses tested, and the programme was not advanced to Phase 3. The safety dossier from those trials is substantial — which is why some researchers still prefer AOD-9604 over the unmodified HGH fragment 176-191 — but the efficacy file remains modest.

Safety and monitoring

Tesamorelin's critical safety biomarker is IGF-1. Because the compound activates endogenous GH release, IGF-1 levels rise — typically held below the upper limit of the age-stratified reference range under the Phase 3 monitoring schedule. Dose reduction triggered at +2 SD from age-norm. Transient glucose-tolerance impairment was observed in the original trials and warrants OGTT monitoring at baseline and at 12 and 26 weeks. Injection-site reactions are the dominant non-systemic AE.

AOD-9604 has the gentler safety profile of the two in the published record. The fragment does not raise IGF-1, does not appear to disturb glucose handling at the doses studied, and Phase 2 reported generally tolerable adverse-event rates. The caveat is that the absence of efficacy in Phase 2 makes the safety record less predictive than it would be in a positive-trial context.

Which to select for research

Choose tesamorelin where the research question concerns the GH axis or where visceral-specific adipose reduction is the primary readout. The Falutz Phase 3 record establishes both the mechanism and the methodology (MRI / CT VAT volumetry) that most modern research designs replicate.

Choose AOD-9604 where the question specifically isolates lipolysis from GH-axis effects — for example, in studies probing β3-adrenergic adipose biology without confounding by IGF-1 rise. The compound's Phase 2 safety record is the strongest asset; researchers planning new adipose-tissue mechanism work routinely cite it as the reference lipolytic fragment.

See also: Full AOD-9604 profile · Full tesamorelin profile · Visceral-adiposity research · GH fragments vs secretagogues review.